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Abstract
Background: Migraine prevention with erenumab and migraine induction by calcitonin gene-related peptide
(CGRP) both carry notable individual variance. We wanted to explore a possible association between individual
efficacy of anti-CGRP treatment and susceptibility to migraine induction by CGRP.
Methods: Thirteen migraine patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody trials,
received CGRP in a double-blind, placebo-controlled, randomized cross-over design to investigate their susceptibility to
migraine induction. A standardized questionnaire was used to assess the efficacy of previous antibody treatment. The
patients were stratified into groups of high responders and poor responders. Primary outcomes were incidence of
migraine-like attacks and area under the curve of headache intensity after infusion of CGRP and placebo. All interviews
and experiments were performed in laboratories at the Danish Headache Center, Copenhagen, Denmark.
Results: Ten high responders and three poor responders were included. CGRP induced migraine-like attacks in ten (77%)
patients, whereof two were poor responders, compared to none after placebo (p = 0.002). The area under the curve for
headache intensity was greater after CGRP, compared to placebo, at 0–90 min (p = 0.009), and 2–12 h (p = 0.014). The
median peak headache intensity score was 5 (5–9) after CGRP, compared to 2 (0–4) after placebo (p = 0.004).
Conclusions: Patients with an excellent effect of erenumab are highly susceptible to CGRP provocation. If an association
is evident, CGRP provocation could prove a biomarker for predicting antibody treatment efficacy.
Trial registration: Retrospectively registered at clinicaltrials.gov with identifier: NCT03481400.
Keywords: Headache, CGRP, Biomarker, Monoclonal antibody
Background
Clinicians treating migraine have, until now, been limited
to preventive drugs that were initially developed for
cardiovascular, psychiatric or neurological diseases other
than migraine. [1] Four anti calcitonin gene-related pep-
tide (anti-CGRP) monoclonal antibodies (mAbs) are in
late-phase development as the first class of preventive
therapeutics targeting migraine-specific mechanisms. [2]
Three mAbs (fremanezumab, eptinezumab and galcanezu-
mab) are ligand specific, and bind to CGRP, while one
(erenumab) binds to the receptor complex (Fig. 1). [3–6]
Overall efficacy and tolerability between the four
antibodies are quite similar, but individual efficacy is wide-
spread. While some patients report excellent efficacy, 35%
report less than 50% reduction in monthly migraine days
when treated with erenumab. [7] The question is whether
we can identify which patients to treat with the new
therapeutics by predicting efficacy response and thereby
introduce personalized treatment schemes.
Calcitonin gene-related peptide induces migraine-like
attacks in an average of 62% of migraine patients across
placebo-controlled and open-label provocation studies.
[8–11] Individual differences in mAb efficacy and
migraine induction suggest that CGRP involvement in mi-
graine varies between patients, and susceptibility to provo-
cation could be a possible biomarker for anti-CGRP
treatment efficacy.
We sought to investigate a possible association
between anti-CGRP treatment efficacy and susceptibility
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to CGRP-induced migraine-like attacks. Our hypotheses
were that CGRP would conduce to a small migraine-like
attack rate in a group of patients with little to no effect
of erenumab and a large attack rate in a group who ex-
perienced an excellent effect of erenumab.
Methods
Recruitment process
Patients, who had participated in the episodic and chronic
erenumab trials (ClincalTrials.gov IDs: NCT02483585 and
NCT02066415), were recruited from the Danish Headache
Center. These patients were contacted and enrolled after
completing their participation in the mAb trial. Patients,
who were likely eligible for participation in up-coming
anti-CGRP mAbs clinical trials, were recruited from the
Danish Headache Center as well. The patients were en-
rolled from July 25 2016 to June 21 2017. Inclusion criteria:
migraine with and/or without aura according to the Inter-
national Classification of Headache Disorders (ICHD-3
beta) [12], age 18 to 65 years, and previous/probable par-
ticipation in an anti-CGRP mAb trial. Exclusion criteria:
use of pharmacological agents (except contraceptives and
preventive migraine medication), cardiovascular disease
and other serious somatic or psychiatric disorders.
Study design
Response to anti-CGRP mAb treatment was evaluated
using a standardized questionnaire (Fig. 2). Patients
rated treatment efficacy for reduction in: migraine days,
headache days, days using rescue medication, and head-
ache intensity. Treatment efficacy was assessed based
on the patients’ last month of receiving mAbs. Patients,
who reported an excellent effect of treatment (efficacy
score ≥ 50%) in at least two of the four outcome vari-
ables, were defined as high responders. The remaining
patients were defined as poor responders.
Patients received 1.5 μg/min human α-CGRP (PolyPep-
tide, Strasbourg, France) and placebo isotonic saline as in-
fusions over 20 min on two separate study days in a
double-blind, placebo-controlled, randomized, cross-over
design.
Experimental protocol
Patients reported to the clinic headache-free for at least
48 h. Coffee, tea, cocoa, cola, tobacco, and alcohol were
not allowed for 12 h before study start. Patients were
instructed to fast for four hours before study start. Fer-
tile female participants underwent a pregnancy test upon
arrival at the hospital.
Fig. 1 Intracellular signaling pathways of calcitonin gene-related peptide receptor activation. One effect of CGRP receptor activation is adenylate
cyclase-mediated cyclic adenosine monophosphate (cAMP) elevation, which leads to protein kinase A (PKA) activation, and activation of multiple
targets depending on cell type. Nitric oxide synthesis may be the result of nitric oxide synthase (NOS) phosphorylation, gene transcription
changes may be a result of cAMP response element binding protein (CREB) activation, and relaxation of vascular smooth muscle cells is partly a
result of ATP-sensitive potassium channels (K+ channels) activation
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Patients underwent a medical examination on the first
study day. A venous catheter was inserted into a cubital
vein, followed by rest in supine position for 30 min, be-
fore initiating the infusion. Intensity and characteristics
of headache, heart rate (HR), blood pressure, and ad-
verse events were registered every 10 min from 10 min
before to 90 min after infusion.
Headache intensity and characteristics
Headache intensity was rated based on a 0 to 10 nu-
meric rating scale (NRS) where ‘0’ denoted no headache,
and ‘10’ the worst possible headache.
Headache characteristics were recorded using a stan-
dardized questionnaire including headache intensity, lo-
cation, quality, aggravation by physical activity, and
accompanying symptoms.
Upon discharge from the hospital, patients were
instructed to self-report headache intensity and charac-
teristics in a standardized headache diary hourly from 2
to 12 h after infusion start. Patients were allowed to use
their usual migraine medication after discharge.
Migraine-like attack criteria
Pharmacologically-induced migraine attacks are not spon-
taneous attacks, and cannot fulfill the ICHD-3 beta cri-
teria. [12] Therefore, modified criteria for
experimentally-induced attacks were developed based on
the following considerations. [13, 14] Firstly, the majority
of patients report that the induced attacks mimic their
spontaneous attacks. [10, 15] Secondly, spontaneous mi-
graine attacks mostly develop in a matter of hours, and in
the beginning of the attack phenomenologically fulfill the
criteria for tension-type headache. Only hereafter, the
headache worsens, becomes unilateral and presents the
associated symptoms required for a migraine diagnosis. Fi-
nally, most patients can predict an impending migraine at-
tack in the early attack stage and cannot be denied
treatment in an experimental setting. Thus, induced
Fig. 2 Questionnaire used for monoclonal antibody response stratification. Patients who reported excellent effect of treatment (efficacy score≥ 50%)
in at least two of the four outcome variables (i-iv) were defined as high responders. The remaining patients were defined as poor responders
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attacks are frequently treated before all migraine criteria
are fulfilled. Accordingly, we used the following two cri-
teria to define a pharmacologically-induced migraine-like
attack [14]:
The headache fulfills criteria C and D of the ICHD-3
beta [12].
C: Headache has at least two of the following
characteristics: Unilateral location, pulsating quality,
moderate to severe intensity, or aggravation by physical
activity.
D: At least one of the following accompanying
symptoms: Nausea and/or vomiting, or photophobia
and phonophobia.
or
Headache described as mimicking the patient’s spontan-
eous attack and treated with acute migraine rescue
medication.
Statistical analysis
Headache intensity scores are presented as median
(range). Heart rate and mean arterial pressure (MAP)
are presented as mean ± standard deviation under the
assumption that they adhere to a normal distribution.
Primary endpoints were incidence of migraine-like at-
tacks from 0 to 12 h after infusion and area under the
curve (AUC), using the trapezoidal rule [16], for head-
ache intensity score at 0 to 90 min and 90 min to 12 h
on the CGRP day, as compared to the placebo day for all
patients. McNemar’s test and Wilcoxon signed-rank test
were used as appropriate. Secondary endpoints were HR
and MAP, which were compared between the two study
days using paired t-tests. Peak headache intensity score
and time to peak headache were compared between
the study days using Wilcoxon signed-rank test. Ad-
verse events are reported as incidences on the CGRP
and placebo day and compared between days using
McNemar’s test in explorative analysis. Predictive
values, sensitivity and specificity were also calculated
as post hoc analyses.
Separate meaningful inference statistics within each
mAb response groups could not be performed due to
small subgroup sample sizes. Data from patients without
previous experience from the erenumab trials were ex-
cluded from the final analyses as this recruitment was
limited by the competitive enrollment strategies of the
anti-CGRP mAbs clinical trials. No statistical power cal-
culation was conducted prior to the study as the sample
size was based on the available data. R (Version 3.4.2)
was used to conduct the statistical analyses. P values are
reported as two-tailed with a 5% level of significance.
Results
Participants
Thirteen patients (12 women) completed the study (Fig.
3). Seven were enrolled from the episodic migraine erenu-
mab trial (ClincalTrials.gov ID: NCT02483585), and six
were enrolled from the chronic migraine erenumab trial
(ClincalTrials.gov ID: NCT02066415). All 13 patients
were enrolled after completing the safety follow-up visit
12 weeks after the last dose of erenumab. Mean age was
39 years (standard deviation ±11 and range 22 to 53).
Clinical characteristics, migraine incidence and intensity
Headache characteristics and accompanying symptoms
are presented in Table 1. Ten of 13 patients (77%) devel-
oped migraine-like attacks after CGRP, compared to
none after placebo (p = 0.002) (Fig. 4). Two of the 10 pa-
tients, who experienced migraine-like attacks, reported
poor response to treatment (patients 5 and 12).
The three patients, who did not develop migraine-like
attacks after CGRP, were chronic migraine patients (pa-
tients 9, 10 and 11). One of these patients (patient 11)
was a poor responder with an efficacy score of zero for
all four outcome variables. The other two patients were
high responders (patients 9 and 10).
The AUC for headache intensity was greater after
CGRP compared to placebo at both 0 to 90 min (p =
0.009) and 2 to 12 h (p = 0.014) (Fig. 5). The median
peak headache intensity score was 5 (5 to 9) after CGRP,
compared to 2 (0 to 4) after placebo (p = 0.004). Time to
peak headache was 180 min (110 to 270) after CGRP
and 330 min (72.5 to 660) after placebo (p = 0.250).
Vital signs and adverse events
The AUC for HR was higher (p < 0.001) and AUC for
MAP was lower (p < 0.001) after CGRP compared to pla-
cebo. All patients reported warm sensations (13/13
(100%)) after CGRP compared to only one patient report-
ing warm sensation (1/13, (8%)) after placebo (p < 0.001).
Flushing was observed after CGRP in all patients (13/13
(100%)) compared to none after placebo (p < 0.001). Five
of 13 patients (63%) reported palpitations after CGRP,
compared to two of 13 (15%) after placebo (p = 0.014).
Predictive values, sensitivity and specificity
Positive predictive value for CGRP-induced attacks in
erenumab high responders was 0.80 (95% CI 0.49 to
0.96) and sensitivity was 0.80 (95% CI 0.66 to 0.89).
Negative predictive value was 0.33 (95% CI 0.08 to 0.73)
and specificity was 0.33 (95% CI 0.01 to 0.91).
Discussion
Our major finding was that patients with response to ere-
numab showed hypersensitivity to CGRP infusion in a
placebo-controlled experiment. In addition to a high
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migraine induction rate (77%), compared to previous stud-
ies, participants also reported moderate to severe (median
peak intensity of 5, range 5 to 9) and long-lasting head-
aches (Fig. 5), which further points toward high CGRP
susceptibility. Previous studies reported median peak
headache intensities ranging from 1 to 4. [9, 10]
Mechanisms of migraine initiation by CGRP and mi-
graine prevention by anti-CGRP mAbs are unknown. Cal-
citonin gene-related peptide is expressed in the trigeminal
C fibers [17], trigeminal ganglion [18] and trigeminal nu-
cleus caudalis [19], and its receptors are expressed in vas-
cular smooth muscle cells [20], A-delta fibers [17] and
trigeminal ganglia. [18] Calcitonin gene-related peptide
binds to its receptor and activates multiple intracellular
signaling pathways of which the most well-known is acti-
vation of adenylate cyclase and formation of cyclic adeno-
sine monophosphate (cAMP). [21] In arteries, this leads to
dilation through an endothelial-dependent synthesis of ni-
tric oxide or relaxation of vascular smooth muscle cells via
opening of ATP-sensitive potassium channels (Fig. 1). [22,
23] In trigeminal ganglion cells, the cAMP increase may
cause sensitization of nociceptive neurons through upreg-
ulation of gene transcription and algogenic receptors in
the cell membranes. [21, 24] In healthy volunteers, CGRP
modulates inputs from noxious heat stimulation of the tri-
geminal area in the brain stem and insula. [25] The
phosphodiesterase-3 inhibitor, cilostazol, potentiates the
accumulation of cAMP in a receptor independent manner,
and induces migraine in 86% of patients [26, 27], support-
ing the notion that cAMP upregulation may induce mi-
graine. To what extent erenumab interacts with these
mechanisms and exerts its anti-migraine effect is not fully
clarified. Interestingly, erenumab inhibits CGRP-driven in-
creases in dermal blood flow after capsaicin injections sug-
gesting peripheral effects of CGRP receptor blockage. [28]
Our study explored a possible association between
self-reported erenumab efficacy and sensitivity to mi-
graine induction by CGRP. Identifying a link between
poor response to mAb treatment and not developing mi-
graine when challenged with CGRP (a so-called
non-CGRP phenotype) could provide a biomarker for
treatment response. In an effort to provide test reliability
Contacted
n = 48
No contact
n = 9
Included in analysis 
n = 13
Not eligible
n = 4
Not interested
n = 12
Enrolled 
n = 23
Lost to follow-up
n = 4
Withdrawal of consent
n = 1
Not eligible for 
provocation
n = 5
Erenumab trials
episodic: n = 18
chronic: n = 24
Eligible participants for 
future anti-CGRP mAb
trials
n = 7
Ongoing trial
participation
n = 1
Fig. 3 Inclusion flowchart. Twenty-three patients were enrolled in the study. Ten of these were excluded subsequently. One patient was excluded due to
a cardiac conduction disease and one due to diabetes mellitus (well-regulated), according to the conventional CGRP provocation protocol. Three patients
were excluded from analysis as they did not participate in the erenumab trials. One patient withdrew consent before the experiments. Four patients were
lost to follow-up and one of these had participated in the first study day. Data from these days were excluded from analyses. Of the ten patients, who were
excluded, seven had received erenumab and six of these were high responders. Response status was not obtained from the last of the seven subjects
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measures, we calculated predictive values, sensitivity and
specificity as post hoc analyses. Positive predictive value
and sensitivity for CGRP-induced attacks in erenumab
high responders were high. In contrast, negative predict-
ive value and specificity were low, impaired by the small
sample of erenumab poor responders. We evaluated ere-
numab treatment response using four variables: reduc-
tion in migraine days, reduction in headache intensity,
reduction in headache days and reduction in days using
rescue medication. Our predefined criteria for “poor re-
sponse” identified three such participants (subjects 5, 11
and 12 in Table 1). One of these was a non-responder
who scored zero in all four efficacy variables. This par-
ticipant reported no migraine after CGRP infusion. The
other two poor responders reported migraine-like at-
tacks after CGRP. We obtained treatment efficacy from
19 patients (Fig. 3) and only the three above-mentioned
patients reported “poor response”. Therefore, we could
not include enough poor responders to calculate a cor-
relation to low migraine induction, which is a limitation.
Furthermore, we cannot ignore the fact that having a
poor response to erenumab in mAb trials might affect a
patient’s willingness to participate in our study,
Fig. 4 Proportion of patients who developed migraine-like attacks
and headache after CGRP and placebo. More patients developed
migraine-like attacks after CGRP (n = 10), compared to placebo
(n = 0) (p = 0.002)
Fig. 5 Headache intensity after CGRP and placebo. Individual headache intensity scores on the CGRP day (a) and placebo day (b). Black lines:
Median intensity at each time point. The median headache intensity was 0 for all time points after placebo. The median time (range) to onset of
migraine was 50 min (20–152.5) after CGRP
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subsequently leading to sampling bias. Our findings sug-
gest that having a positive response to erenumab, based
on our questionnaire variables, is associated with a high
susceptibility to migraine induction by CGRP. The lack of
a larger group of poor responders inhibits us from draw-
ing conclusions on a possible association between those
patients and a low susceptibility to CGRP. The question
remains whether a CGRP provocation model can be used
to predict efficacy of anti-CGRP mAb treatment when it
becomes available. A large-scale prospective provocation
study in patients, before they receive anti-CGRP treat-
ment, would allow us to draw conclusions on poor re-
sponders i.e. patients with a possible non-CGRP migraine
phenotype. When a sufficient number of non-responders
have been provoked, we will be able to determine if the
CGRP model of migraine is a biomarker for treatment re-
sponse. Consequently, we will be able to provide bio-
marker reliability tests with sensitivity and specificity as
outcome measures.
Conclusion
In this study we showed high migraine induction capabil-
ities with CGRP in migraine patients who responded to ere-
numab treatment compared to data from previous CGRP
provocation experiments. [8–11] If an association between
poor migraine induction and poor treatment efficacy is also
evident, the CGRP model of migraine could become the
basis for a biomarker for mAb treatment response. Such a
biomarker would be a powerful tool for clinicians choosing
therapeutics for the prevention of migraine.
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